Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

 

 

 

 

Peer-reviewed data for Pfizer Inc.’s BNT162b2 mRNA COVID-19 vaccine candidate was published by the New England Journal of Medicine (NEJM), confirming its safety and efficacy. The study’s authors concluded that a two-dose regimen of BNT162b2 conferred 95% protection against COVID-19 in individuals 16 years of age or older, with safety over a median of two months similar to that of other viral vaccines.

 

You can read the full article here: https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=featured_home